文献速递脑血管病

随机对照试验的脆弱指数荟萃分析显示,3小时内静脉阿替普酶治疗的获益证据强度极高

Fragility Index Meta-Analysis of Randomized Controlled Trials Shows Highly Robust Evidential Strength for Benefit of <3 Hour Intravenous Alteplase.
PubMed 文献 · Stroke · 2022-05-11

该研究通过累积脆弱指数(FI)分析,评估静脉阿替普酶在发病3小时内治疗致残性急性缺血性卒中的证据强度。研究纳入1995年至2021年的9项随机对照试验,进行研究水平荟萃分析及个体参与者水平分析。结果显示,阿替普酶提高无残疾生存(mRS 0-1)和功能独立(mRS 0-2),不改变死亡率;总体FI分别为42和40,均属高度稳健,且证据强度随时间保持高度稳健。

要点

  • 静脉阿替普酶3小时内治疗急性缺血性卒中,无残疾生存(mRS 0-1)的FI为42,高度稳健。
  • 功能独立(mRS 0-2)的FI为40,高度稳健;死亡率无显著差异。
  • 证据强度自1995年两项NINDS试验后为稳健,2012年升至高度稳健,2021年仍高度稳健。

核心结论

  • 发病3小时内静脉阿替普酶治疗急性缺血性卒中,是医学界证据最稳健的治疗方法之一。
  • 25年前的最初同期试验显示获益证据稳健,经过后续研究,证据升级为高度稳健。

研究设计与样本

  • 对1995年至2021年的9项随机对照试验进行荟萃分析,包括研究水平荟萃分析和个体参与者水平荟萃分析。
  • 在每个 successive 随机对照试验后,连续进行个体试验和累积脆弱指数分析。
  • 脆弱指数分类:不稳健(FI 0-4)、有些稳健(FI 5-12)、稳健(FI 13-33)、高度稳健(FI >33)。

主要发现

  • 研究水平荟萃分析中,阿替普酶提高无残疾生存(mRS 0-1):31.0% vs 22.3%,相对风险1.39(95% CI 1.20-1.61),P<0.00001。
  • 阿替普酶提高功能独立(mRS 0-2):39.7% vs 31.2%,相对风险1.29(95% CI 1.14-1.45),P<0.000。
  • 阿替普酶未改变死亡率:24.1% vs 26.1%,P=0.23。
  • 研究水平荟萃分析的总体FI:mRS 0-1为42,mRS 0-2为40,均高度稳健。
  • 连续FI分析显示,1995年两项NINDS-tPA试验发表后,阿替普酶 superior 的证据强度为稳健;2012年升至高度稳健;2021年仍高度稳健。

关键数值与推荐

  • 无残疾生存(mRS 0-1)的FI为42,高度稳健。
  • 功能独立(mRS 0-2)的FI为40,高度稳健。
  • 死亡率差异无统计学显著(P=0.23)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cumulative fragility index (FI) analysis enables quantification of the evidential strength of intravenous alteplase's core indication-treatment of disabling acute ischemic stroke within 3 hours of onset. METHODS: Meta-analyses were performed (study level) or identified (individual participant level) for freedom-from-disability (modified Rankin Scale [mRS] score 0-1, primary efficacy), functional independence (mRS score 0-2, secondary efficacy), and mortality outcomes. Individual trial and cumulative FI analyses were serially conducted after each successive randomized controlled trial (RCT). FI scores were classified as follows: not robust (FI 0-4), somewhat robust (FI 5-12), robust (FI 13-33), and highly robust (FI >33). RESULTS: Nine randomized controlled trials were identified from 1995 to 2021 of within-3-hour intravenous alteplase for acute ischemic stroke. In study-level meta-analyses, alteplase increased freedom-from-disability outcome (mRS score 0-1), 31.0% versus 22.3%, relative risk, 1.39 (95% CI, 1.20-1.61); P<0.00001; increased functional independence (mRS score 0-2), 39.7% versus 31.2%, relative risk, 1.29 (95% CI, 1.14-1.45), P<0.000; and did not alter mortality, 24.1% versus 26.1%; P=0.23. Overall FIs for study-level meta-analyses were both highly robust at 42 and 40 for mRS score 0-1 and mRS score 0-2, respectively. Serial FI analyses showed robust evidential strength for intravenous alteplase superiority with publication of the 2 NINDS-tPA trials (National Institute of Neurological Disorders and Stroke-tissue-type plasminogen activator) in 1995, increased to highly robust in 2012, and remains highly robust in 2021. CONCLUSIONS: Within-3-hour intravenous alteplase for acute ischemic stroke is one of the most robustly proven therapies in medicine. The initial concurrent trials 25 years ago showed robust evidence for benefit and, after additional studies, advanced to highly robust.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Mun KT, Bonomo JB, Liebeskind DS, et al. Fragility Index Meta-Analysis of Randomized Controlled Trials Shows Highly Robust Evidential Strength for Benefit of <3 Hour Intravenous Alteplase. Stroke. 2022. PMID: 35543129. doi:10.1161/STROKEAHA.121.038153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。